This trial is active, not recruiting.

Condition thoracic injuries
Treatment gore conformable tag thoracic endoprosthesis
Sponsor W.L.Gore & Associates
Start date November 2009
End date February 2011
Trial size 51 participants
Trial identifier NCT00917852, TAG 08-02


TAG 08-02 is a prospective, multicenter, single-arm study to evaluate the use of the CTAG Device in traumatic transection of the descending thoracic aorta.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
gore conformable tag thoracic endoprosthesis
Endovascular stent graft

Primary Outcomes

All Cause Mortality
time frame: 30 days post-treatment

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Traumatic transection of the DTA that requires repair, determined by the treating physician 2. Traumatic aortic transection location between, but does not include, the left subclavian artery and celiac artery 3. Endovascular repair with the GORE Conformable TAG® Device performed less than or = to 14 days after aortic injury 4. Age greater than or equal to 18 years 5. Proximal and distal landing zone length greater than or equal to 2.0 cm. Landing zones must be in native aorta. Landing zone may include left subclavian artery, if necessary 6. All proximal and distal landing zone inner diameters are between 16-42 mm. Diameter assessed by flow lumen and thrombus, if present; calcium excluded 7. Subject capable of complying with study protocol requirements, including follow-up 8. Informed Consent Form signed by subject or legal representative Exclusion Criteria: 1. Differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to compensate for the taper 2. Tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access 3. Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s) 4. Infected aorta 5. Subject has a systemic infection and may be at increased risk of endovascular graft infection 6. Planned coverage of left carotid or celiac arteries with the CTAG Device 7. Known degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome 8. Treatment in another drug or medical device study within 1 year of study enrollment 9. Known history of drug abuse 10. Pregnant female 11. Moribund patient not expected to live 24 hours with or without operation, determined by the treating physician 12. Injury Severity Score of 75 13. Subject has known sensitivities or allergies to the device materials

Additional Information

Official title Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Traumatic Transection of the Descending Thoracic Aorta
Principal investigator Mark Farber, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by W.L.Gore & Associates.